{"article_title": "Alzheimer\u2019s Drug Is a Big Bet for Lilly", "article_keywords": ["ultimately", "worsening", "big", "washington", "drug", "lillys", "trial", "underlying", "alzheimers", "lilly", "studies", "bet", "treatment"], "article_url": "http://www.wsj.com/articles/alzheimers-drug-is-a-big-bet-for-lilly-1437211800", "article_text": "Researchers will provide clues about whether Eli Lilly & Co.\u2019s risky bet on an experimental drug for Alzheimer\u2019s disease ultimately pays off\u2014for patients and for Lilly\u2019s bottom line.\n\nScientists are scheduled to present results from a clinical trial of the drug, solanezumab, at the Alzheimer\u2019s Association International Conference in Washington. The outcomes will help signal whether Lilly\u2019s drug can overcome earlier, negative studies and become the first marketed treatment to slow the worsening of the underlying...", "article_metadata": {"article.template": "snippet", "article.created": "2015-07-18T09:30:00.000Z", "article.section": "Business", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "Researchers will provide clues about whether Lilly\u2019s risky bet on an experimental drug for Alzheimer\u2019s disease ultimately pays off\u2014for patients and for the company\u2019s bottom line.", "creator": "@Loftus", "image": {"src": "https://si.wsj.net/public/resources/images/BN-JL330_0717co_G_20150717155359.jpg", "alt": "Researchers will provide clues about whether Lilly\u2019s bet on an Alzheimer\u2019s drug pays off", "identifier": "https://si.wsj.net/public/resources/images/BN-JL330_0717co_D_20150717155359.jpg"}, "title": "Alzheimer\u2019s Drug Is a Big Bet for Lilly", "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB11354386136995374337504581112273683586168&headline=Researchers%20will%20provide%20clues%20about%20whether%20Lilly%u2019s%20bet%20on%20an%20Alzheimer%u2019s%20drug%20pays%20off&weburl=http://www.wsj.com/articles/SB11354386136995374337504581112273683586168"}}, "page.site.product": "WSJ", "keywords": "alzheimer's disease treatment,alzheimer's drug development,alzheimer's research,amyloid hypothesis,lilly,Eli Lilly,LLY,research,development,corporate,industrial news,new product,service testing,political,general news,dementia,health,medical conditions,mental health,medical treatments,procedures,pharmaceuticals,health care,life sciences", "news_keywords": "alzheimer's disease treatment,alzheimer's drug development,alzheimer's research,amyloid hypothesis,lilly,Eli Lilly,LLY,research,development,corporate", "article.headline": "Researchers will provide clues about whether Lilly\u2019s bet on an Alzheimer\u2019s drug pays off", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/BN-JL330_0717co_E_20150717155359.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/BN-JL330_0717co_D_20150717155359.jpg"}}, "description": "Researchers will provide clues about whether Lilly\u2019s risky bet on an experimental drug for Alzheimer\u2019s disease ultimately pays off\u2014for patients and for the company\u2019s bottom line.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB11354386136995374337504581112273683586168&headline=Researchers%20will%20provide%20clues%20about%20whether%20Lilly%u2019s%20bet%20on%20an%20Alzheimer%u2019s%20drug%20pays%20off&weburl=http://www.wsj.com/articles/SB11354386136995374337504581112273683586168", "user.type": "nonsubscriber", "article.page": "Health Care", "page.content.format": "responsive", "article.summary": "Researchers will provide clues about whether Lilly\u2019s risky bet on an experimental drug for Alzheimer\u2019s disease ultimately pays off\u2014for patients and for the company\u2019s bottom line.", "page.site": "wsj", "testkeys": "C", "article.published": "2015-07-18T09:30:00.000Z", "dj.asn": "i-c642", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"internal_link_count": 1, "image_count": 1, "word_count": 730, "publisher": "https://www.facebook.com/wsj"}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "Researchers will provide clues about whether Lilly\u2019s risky bet on an experimental drug for Alzheimer\u2019s disease ultimately pays off\u2014for patients and for the company\u2019s bottom line.", "title": "Alzheimer\u2019s Drug Is a Big Bet for Lilly", "url": "http://www.wsj.com/articles/alzheimers-drug-is-a-big-bet-for-lilly-1437211800", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/BN-JL330_0717co_G_20150717155359.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "Peter Loftus", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Alzheimer\u2019s Drug Is a Big Bet for Lilly", "article.type": "Health", "article.id": "SB11354386136995374337504581112273683586168", "user.exp": "default", "article.updated": "2015-07-18T09:30:00.000Z"}, "article_summary": "Researchers will provide clues about whether Eli Lilly & Co.\u2019s risky bet on an experimental drug for Alzheimer\u2019s disease ultimately pays off\u2014for patients and for Lilly\u2019s bottom line.\nScientists are scheduled to present results from a clinical trial of the drug, solanezumab, at the Alzheimer\u2019s Association International Conference in Washington.\nThe outcomes will help signal whether Lilly\u2019s drug can overcome earlier, negative studies and become the first marketed treatment to slow the worsening of the underlying..."}